Deruxtecan - Drug-Linker Conjugates for ADC - MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEDeruxtecanCat. No.: HY-13631ECAS No.: 1599440-13-7分式: CHFNO分量: 1034.05作靶點(diǎn): Drug-Linker Conjugates for ADC作通路: Antibody-drug Conjugate/ADC Related儲(chǔ)存式: -20C, stored under nitrogen* In solvent : -80C, 6 months; -20C, 1 month (store

2、d undernitrogen)溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 50 mg/mL (48.35 mM)H2O : 0.1 mg/mL (insoluble)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 0.9671 mL 4.8354 mL 9.6707 mL5 mM 0.1934 mL 0.9671 mL 1.9341 mL10 mM 0.0967 mL 0.4835 mL 0.9671 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲(chǔ)備液，并請(qǐng)注

3、意儲(chǔ)備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 DeruxtecanDS-8201 的連接體， 種毒素， 連接橋與藥物的偶聯(lián)物， 抗體-藥物偶聯(lián)物 (ADC) 的部分。詳細(xì)信息請(qǐng)參考專利獻(xiàn) WO2017002776A1 中的化合物 1。IC50 & Target Drug-linker conjugates for ADC 1體外研究Antibody-drug conjugates deliver anticancer agents selectively and efficiently to tumor tissue and have1/2 Master of Smal

4、l Molecules 您邊的抑制劑師www.MedChemEsignificant antitumor efficacy with a wide therapeutic window 2.REFERENCES1. NOGUCHI, Shigeru, et al. METHOD FOR SELECTIVELY MANUFACTURING ANTIBODY-DRUG CONJUGATE. WO2017002776A1.2. Ogitani Y, et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, intumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107(7):1039-46.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820-3792; 021-589559